JAMA

Link Between Starting LDL Cholesterol Levels and Overall and Heart-Related Deaths After Lowering LDL Cholesterol

Updated

Abstract

Effects on specific fatal and nonfatal endpoints vary for LDL-C-lowering drug trials.

  • Different LDL-C-lowering drugs may influence various health outcomes differently.
  • Some trials report changes in fatal endpoints, while others focus on nonfatal events.
  • The variability in effects suggests that not all LDL-C-lowering treatments are equally effective for all health outcomes.
  • Further investigation is needed to understand the specific effects of each drug on these endpoints.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Navarese reported receiving research grants from Amgen and personal fees from Amgen and Sanofi. Dr Robinson reported receiving research grants from Acasti, Amarin, Amgen, AstraZeneca, Esai, Esperion, Merck, Pfizer, Regeneron, Sanofi, and Takeda and receiving personal fees from Akcea/Ioinis, Dr Reddy Laboratories, Eli Lilly, Esperion, Pfizer, Regeneron, and Sanofi. Dr Andreotti reported receiving personal fees from Actelion, Amgen, Bayer, Boehringer-Ingelheim; Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, and the Menarini International Foundation. Dr Tantry reported receiving personal fees from AstraZeneca and Medicure. Dr Raggi reported receiving grants from Amgen and Sanofi. Dr Gurbel reported receiving a grant from Amgen. No other authors reported disclosures.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free